A Phase 3 interventional study of Insulin Degludec and Insulin Aspart in Diabetes, sponsored by Sunshine Lake Pharma Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-01.
Sponsored by Sunshine Lake Pharma Co., Ltd. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 103 studies testing insulin degludec in Diabetes Mellitus — 1 open to participants now, 1 under way, 1 of them phase 3. insulin degludec · Diabetes Mellitus.
Among the 103 studies testing insulin degludec in Diabetes Mellitus, this one is the 33rd largest by enrollment, is one of 2 that started in 2023, is one of 55 in phase 3, and was the 102nd registered.
8,293 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.
Browse Diabetes Mellitus studies →1 of the 103 studies testing insulin degludec in Diabetes Mellitus is open now, in 1 country. Recruiting first, the newest first:
Huashan Hospital · Sites in China
Ages 18–70
By country, each count listing its studies:
insulin degludec: first FDA approval 2015 (RYZODEG 70/30), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 648 Diabetes Mellitus studies recruiting now, 357 (55%) set no upper age limit and 195 (30%) stop at 75 or younger; 88 take children under 18; 182 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
103 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 414 is above the median of 80 across 6,025 interventional studies indexed under Diabetes Mellitus.
Median enrollment 145 across the 103 interventional studies. Of the 101 that completed or were terminated, 55 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
99 of 103 have an industry lead sponsor. The 7 most frequent:
Sunshine Lake Pharma Co., Ltd. is the lead sponsor of 83 studies on the registry; 13 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Sunshine Lake Pharma Co., Ltd. has 1 study filed under Diabetes Mellitus — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 103 studies testing insulin degludec in Diabetes Mellitus, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to see if Insulin Degludec/Insulin Aspart (22011) compared to Insulin Degludec/Insulin Aspart (Ryzodeg) is similar in safety and effect in participants with type 2 diabetes (T2D).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Insulin Degludec and Insulin Aspart
Drug: Insulin Degludec and Insulin Aspart
Drug pages: Insulin degludec · Insulin Aspart
administered subcutaneously, once a day
Change From Baseline in Hemoglobin A1c (HbA1c)
HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time
Time frame: Baseline to Week 24
Change From Baseline in Hemoglobin A1c (HbA1c) in Week 12
HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time
Time frame: Baseline to Week12
Percentage of Participant Who Achieved HbA1c<7% and ≤6.5%
the ratio of participant Who Achieved HbA1c\<7% and ≤6.5%
Time frame: Baseline to Week24
Percentage of Participant Who Achieved HbA1c<7% and ≤6.5% without Hypoglycaemic Episodes
The ratio of participant Who Achieved HbA1c\<7% and ≤6.5% without Hypoglycaemic Episodes
Time frame: Baseline to Week24
Change From Baseline in Fasting Plasma Glucose(FPG)
the plasma glucose concentration on an empty stomach
Time frame: Baseline to Week12
Change From Baseline in Fasting Plasma Glucose(FPG) in Week24
the plasma glucose concentration on an empty stomach
Time frame: Baseline to Week24
Change From Baseline in 7-Point Self-Monitoring Blood Glucose (SMBG) Values
SMBG 7-point profiles were measured at fasting, 2-hour post morning meal, pre midday meal, 2-hour post midday meal, pre evening meal, 2-hours post evening meal, and bedtime.
Time frame: Baseline to Week12
Change From Baseline in 7-Point Self-Monitoring Blood Glucose (SMBG) Values in Week24
SMBG 7-point profiles were measured at fasting, 2-hour post morning meal, pre midday meal, 2-hour post midday meal, pre evening meal, 2-hours post evening meal, and bedtime.
Time frame: Baseline to Week24
Change From Baseline in Body weight
Change in body weight
Time frame: Baseline to Week24
Number of Treatment-emergent Adverse Events (TEAE) and Serious Adverse Events(SAE)
Safety
Time frame: from baseline to Week25
Plan to share: No
No publications or documents are linked to this record.
Ran from Jul 2023 to primary completion in Aug 2024, 13 months.
Of 167 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 23. This study's 13 months is below that.
Counting every sponsor, half of 230 studies reached it within 19 months; a quarter within 13 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Insulin degludec · Insulin Aspart
Sunshine Lake Pharma Co., Ltd. →